Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Blood Sugar Associated with Lower Risk of Benign Tumors

By LabMedica International staff writers
Posted on 07 Jul 2016
Meningioma, is a primary tumor arising from the membrane surrounding the brain and spinal cord, accounts for more than one-third of all primary brain and central nervous system tumors.

The discovery that benign brain tumors that have previously been tied to obesity and diabetes are less likely to emerge in those with high blood sugar and this could shed light on the development of meningiomas, that are usually not cancerous but that can require risky surgery and affect a patient's quality of life.

Scientists at Ohio State University (Columbus, OH, USA) and their Swedish colleagues conducted a cohort study to evaluate the potential effects of obesity-related prediagnostic glucose, triglycerides and cholesterol on meningioma and of prediagnostic meningioma on these biomarkers. More...
They identified 41,355 individuals in the Apolipoprotein MOrtality RISk cohort with values for these biomarkers within 15 years before meningioma diagnosis, death, migration or the end of follow-up.

Meningioma was diagnosed in 181 women and 115 men whose median follow-up time was seven years. Fasting serum glucose level was inversely related to meningioma among women, but not men. Women with the highest fasting blood sugar were less than half as likely as those with the lowest readings to develop a tumor. When they compared the less-reliable non-fasting sugar readings, those taken without a period of no food or drink that could influence the results, they found that both men and women with high blood sugar had a lower likelihood of meningioma diagnosis.

The authors concluded paradoxically, hyperglycemia is inversely associated with meningioma in women. This finding does not necessarily negate the positive role of obesity or diabetes in meningioma development; rather, it may indicate that their effects depend on the stage of development. Furthermore, the prediagnostic tumor may reduce serum cholesterol levels.

Judith Schwartzbaum, PhD, a professor and the lead author of the study, said, “It's so unexpected. Usually diabetes and high blood sugar raises the risk of cancer, and it's the opposite here. These tumors take years to develop, and an earlier diagnosis would certainly lead to better surgical outcomes. It's also possible that sugar levels dip during early tumor development because the tumor is using glucose to grow.” The study was published on June 2, 2016, in the British Journal of Cancer.

Related Links:
Ohio State University


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.